“Kickbacks to middlemen,” AKA rebates.
Vendors in all industries use them as incentives to marketers to sell their products.
But calling them “kickbacks” sounds so much more sinister.
Killing all the hyper-regulation in the pharmaceutical industry would actually accomplish the intended goal.
~~~~~~~~~~~~~~~~~~~
In addition to rebates, the DOJ has prosecuted many large,costly, illicit kick back schemes in the past 2 years.
Not sure why we haven’t been looking at the pharma industry like a monopoly and/or a public utility.
That de-regulation thing could be risky.
I know - don’t Lizzy Warren more ideas.